SelSym Biotech has partnered with Persephoni BioSciences to advance the development of SymClot, a groundbreaking hemostatic therapy that is shelf-stable and does not require blood typing, aimed at improving care during emergencies. This collaboration will allow SelSym to leverage Persephoni’s resources as they prepare for clinical trials, marking their first equity financing. Founded by experts in the field, SelSym has developed its technology from research at North Carolina State University and has received support from significant grant sources.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/persephoni-backs-selsym-biotech-to-bring-blood-type-agnostic-bleeding-control-to-the-point-of-injury/2385096
